What compounded semaglutide is, and where it stands in 2026

Compounded semaglutide uses the same named drug as Ozempic and Wegovy, but nobody at FDA has checked the vial you receive. The agency says plainly that it “does not review compounded drugs for safety, effectiveness or quality before they are marketed” ^[2]. That one fact explains most of what follows: the strength, the add-ins and the quality all depend on the pharmacy that made it.

It copies the molecule, not the product

Compounded semaglutide shares a named active ingredient with Ozempic and Wegovy. Everything around that ingredient comes from the pharmacy. That covers the vial, the strength, any added vitamins and the quality testing. None of it comes from an application FDA reviewed.

Two kinds of makers exist. A 503A pharmacy is a state-licensed pharmacy that compounds for a named patient’s prescription. A 503B outsourcing facility registers with FDA and can make larger quantities, but only from ingredients on a specific FDA list or while a drug is in shortage ^[3]. Most online programs fill compounded semaglutide through a 503A pharmacy.

Brand semaglutide is a different story. FDA approved Ozempic for type 2 diabetes in December 2017 ^[8] and Wegovy for weight management in June 2021 ^[9]. Wegovy now also carries a heart-risk indication and a liver indication (MASH) on its label ^[6].

The last row matters more than it looks. FDA has warned companies that sold semaglutide “falsely labeled ‘for research purposes’ or ‘not for human consumption,’” often with dosing instructions attached ^[2]. Those products have no legal route to a patient at all.

Where the semaglutide itself comes from

Novo Nordisk doesn’t sell its semaglutide to compounders. A compounding pharmacy buys the raw ingredient, called the active pharmaceutical ingredient or API, from a chemical supplier, often overseas. Quality starts there.

FDA has set up a “green list” import alert (66-80) to stop GLP-1 ingredients with “potential quality concerns” at the border ^[2]. The alert doesn’t apply to makers that FDA’s inspections show meet its manufacturing standards. So a pharmacy can still source lawfully, but you can’t see which supplier it used from the vial. That’s one more question for your program: which pharmacy, and does it test each shipment it receives?

What’s in the vial depends on the pharmacy

Two compounded semaglutide products can differ in salt form, added vitamins, concentration and beyond-use date. So no, all compounded semaglutide is not the same.

Salt form. Approved semaglutide is the base molecule. Some compounders have used semaglutide sodium or semaglutide acetate instead. FDA says these “are different active ingredients than are used in the approved drugs” and that it is “not aware of any lawful basis for their use in compounding” ^[2]. If your pharmacy label names sodium or acetate, ask your prescriber about it before the next refill.

Add-ins. Many programs sell semaglutide mixed with vitamin B12, B6 or glycine. Adding a vitamin doesn’t automatically make a product a different drug in FDA’s eyes. FDA’s own example: a semaglutide and B12 injection may still count as “essentially a copy” of the brand when the route matches and the amounts are “within 10% of the strengths of the respective commercially available drug products” ^[1]. How much B12 is in a given vial varies by pharmacy. The pharmacy label is the only place to read it.

Add-ins are common. In a 2025 secret-shopper study of 75 clinics and med spas in West Virginia and Oklahoma, 56.0% offered GLP-1 products combined with B vitamins ^[16]. The same study traced 23 supplier facilities; 4 of 21 checked were not licensed for sterile compounding.

Impurities. A 2026 lab study found different impurity profiles in compounded semaglutide than in the originator product, and larger gaps in strength after light exposure ^[17]. Its authors are Novo Nordisk employees and shareholders, and the work was done in cell and chemistry assays, not in patients. Treat it as a reason to ask questions, not as proof of harm.

Why it became so common: the 2022–2025 shortage

Compounded semaglutide spread because semaglutide injection sat on FDA’s shortage list from 2022 until February 21, 2025 ^[1]. While a drug is in shortage, pharmacies may make copies of it. When FDA declared the shortage resolved, it gave 503A pharmacies until April 22, 2025 and 503B facilities until May 22, 2025 to wind down.

Where it stands legally today: narrow, patient-specific, not routine

Today a 503A pharmacy may compound semaglutide only on a patient-specific prescription. It may not make copies of the brand “regularly or in inordinate amounts.” FDA has said it won’t act against a compounder that fills “four or fewer prescriptions of that compounded drug product during a calendar month” ^[1].

There is one exception. A copy is allowed when “a prescriber determines and documents the compounded drug product contains a change that produces a significant difference from the commercially available drug product for an identified individual patient” ^[1]. That’s why so many programs call their product “personalized.” The word alone doesn’t satisfy the rule; the documented reason does.

Outsourcing facilities face a tighter wall. FDA’s April 2026 reminder says semaglutide does “not currently appear on the 503B bulks list or on FDA’s drug shortage list” ^[1]. In April 2026 FDA proposed keeping it off that list for good, “finding no clinical need” for outsourcing facilities to compound it from bulk ^[3]. The comment period ran to July 30, 2026 ^[5]. For what a final decision would change, see whether compounded semaglutide will be banned.

Does compounded semaglutide work like Wegovy? No trial has tested it

No trial has tested any compounded semaglutide product. The weight-loss numbers people quote come from Wegovy’s trials. In STEP 1, 1,961 adults without diabetes lost 14.9% of body weight on 2.4 mg weekly over 68 weeks, against 2.4% on placebo ^[12].

If the product matches the brand in dose and quality, you’d expect similar effects. That “if” is exactly what no one has measured. More on the evidence and its limits is in does compounded semaglutide work.

What FDA has flagged on safety

FDA’s concerns are specific: dosing errors with multi-dose vials, salt forms, fraudulent labels, warm shipments and a growing count of adverse-event reports. As of May 31, 2026, FDA had received 990 reports tied to compounded semaglutide, and it says such events are likely underreported ^[2].

• Dosing errors. FDA has received reports, “some requiring hospitalization,” that may be linked to dosing errors with compounded injectable semaglutide ^[2].
• Vials past 28 days. FDA recommends multi-dose vials of sterile medicine be used within 28 days of first use, even if the compounder’s label says longer ^[2].
• Warm deliveries. FDA recommends not using any injectable GLP-1 that “arrives warm or with insufficient refrigeration” ^[2].
• Fake pharmacies. FDA has seen labels naming pharmacies that don’t exist, or that didn’t make the product ^[2].

The brand labels also carry a boxed warning. Semaglutide caused thyroid C-cell tumors in rodents, and it isn’t known whether it does in people; it’s not for anyone with a personal or family history of medullary thyroid cancer or MEN 2 ^[6]. A compounded product doesn’t escape that risk by skipping the label.

The everyday side effects are the same ones the brand label lists. The most common, in at least 5% of people on Wegovy, are nausea, diarrhea, vomiting, constipation, stomach pain, headache, tiredness, indigestion, dizziness, bloating, burping, gas, reflux and hair loss ^[6]. In STEP 1, 4.5% stopped treatment because of stomach side effects, against 0.8% on placebo ^[12]. The label also warns about pancreatitis, gallbladder problems and kidney injury from dehydration. Those rates come from the brand at labeled doses; a vial that holds more or less than its label says can shift them. The full safety picture, side effects included, is in is compounded semaglutide safe. Storage questions are covered in keeping compounded semaglutide in the fridge.

Forms you’ll see: injections, drops, lozenges and tablets

Most compounded semaglutide is a weekly injection from a multi-dose vial. Some programs also sell sublingual drops, lozenges, dissolving tablets or capsules. None of those has an FDA-approved counterpart, and no published trial shows how much semaglutide they deliver.

That’s a real gap. Novo Nordisk’s approved semaglutide tablets rely on an absorption enhancer called SNAC and a strict morning fasting routine, and even then only about 1% to 2% of the dose is absorbed ^[6]. A compounded drop or lozenge has no such data behind it. The approved pills are explained in oral semaglutide.

What compounded semaglutide costs right now

Across 72 online programs, compounded semaglutide injections run $75–$349 a month as of this update, on the plan most people start with. The table puts each program’s monthly price next to how it bills. Watch for prepaid packages and four-week billing, which change what a year costs.

Three things move the number. First, dose: some programs, such as Midi Health, charge more as the dose rises, while others keep one flat price. Second, billing cycle: a plan billed every four weeks charges 13 times a year, not 12, so the monthly figure in the table already counts that. Third, prepaying: three- and twelve-month packages lower the monthly rate but lock in your money before you know how you’ll tolerate the drug. Ask what happens to a prepaid balance if your prescriber stops treatment.

Also offered by (no standing monthly price published): Midi Health.

Brand semaglutide now competes on price too. NovoCare’s self-pay offer lists Wegovy pens at $199 a month for the first two fills for new patients at the two lowest doses, through December 31, 2026, then $349 a month ^[10]. The Wegovy pill starts at $149 a month for the 1.5 mg tablet. The full cost breakdown, including what changes the price, is in how much compounded semaglutide costs. Programs side by side are on the compounded semaglutide providers scorecard.

Compounded semaglutide vs compounded tirzepatide: different molecules

Tirzepatide is a different drug that acts on two hormone receptors (GIP and GLP-1) instead of one. Head to head, the brand versions weren’t close: in SURMOUNT-5, people on tirzepatide lost 20.2% of their weight at 72 weeks, against 13.7% on semaglutide ^[15]. That trial used Zepbound and Wegovy, not compounded products. The compounded version is covered in compounded tirzepatide explained, and the brand drugs are compared in semaglutide vs tirzepatide.

The long-run question: what happens when you stop

Semaglutide works while you take it. In the STEP 1 extension, people who stopped after 68 weeks regained about two-thirds of the weight they had lost within a year, and their blood pressure and cholesterol gains faded too ^[13]. That’s brand data, but it applies to the molecule.

So the real cost of compounded semaglutide is the monthly price times the years you expect to stay on it. A product that’s cheap now but legally uncertain carries a second cost: the chance that you’ll need to switch mid-course. If your goal is metabolic health for the next decade, not just this year, plan for both. The heart benefit seen in SELECT came after more than three years of treatment with the brand ^[14].

Questions to ask a prescriber before you start

1. Which pharmacy will fill my prescription, and is it licensed in my state?
2. Is the ingredient semaglutide base, or a salt form such as sodium or acetate?
3. What else is in the vial, and at what strength?
4. What documented reason makes this compounded product right for me instead of Wegovy or Ozempic?
5. Who answers my questions after the medicine arrives, and how fast?
6. If the rules change, what’s the plan to move me to a brand product?

How to tell if your semaglutide is compounded

Brand semaglutide arrives as a Novo Nordisk pen, prefilled syringe or tablet bottle with the Ozempic, Wegovy or Rybelsus name on it ^{[6] [7]}. Compounded semaglutide arrives in a vial, dropper bottle or blister pack labeled by the compounding pharmacy, with that pharmacy’s name and address.

• A Novo Nordisk pen or tablet bottle with a brand name is the approved drug.
• A pharmacy-labeled vial, often with “B12” or another add-in in the name, is compounded.
• No pharmacy name, a misspelled label or an address you can’t find is one of FDA’s red flags ^[2].

You can check a pharmacy’s license with your state board of pharmacy. FDA’s BeSafeRx page explains how to spot an online pharmacy that isn’t licensed ^[11]. The difference from the brand product in detail is in compounded semaglutide vs Ozempic.

How to get it, and the brand routes that now compete

Compounded semaglutide needs a prescription from a licensed clinician, usually through a telehealth program. Programs such as Eden and Embody name the pharmacy that fills their orders on their own sites; Strut Health sells both an injection and a lozenge. Ask any program which pharmacy fills your order before you pay.

Step-by-step access, from intake to delivery, is in how to get compounded semaglutide. If you’re weighing a smaller dose for other goals, read microdosing GLP-1s first; no trial has tested it.